- Home
- KTCC vs VYNE Comparison
KTCC vs VYNE Comparison
Compare KTCC & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTCC
- VYNE
- Stock Information
- Founded
- KTCC 1969
- VYNE 2003
- Country
- KTCC United States
- VYNE United States
- Employees
- KTCC N/A
- VYNE N/A
- Industry
- KTCC Electrical Products
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- KTCC Technology
- VYNE Health Care
- Exchange
- KTCC Nasdaq
- VYNE Nasdaq
- Market Cap
- KTCC 34.0M
- VYNE 35.7M
- IPO Year
- KTCC N/A
- VYNE 2018
- Fundamental
- Price
- KTCC $2.62
- VYNE $1.58
- Analyst Decision
- KTCC
- VYNE Strong Buy
- Analyst Count
- KTCC 0
- VYNE 2
- Target Price
- KTCC N/A
- VYNE $6.88
- AVG Volume (30 Days)
- KTCC 29.7K
- VYNE 192.5K
- Earning Date
- KTCC 05-06-2025
- VYNE 03-06-2025
- Dividend Yield
- KTCC N/A
- VYNE N/A
- EPS Growth
- KTCC N/A
- VYNE N/A
- EPS
- KTCC N/A
- VYNE N/A
- Revenue
- KTCC $514,394,000.00
- VYNE $501,000.00
- Revenue This Year
- KTCC N/A
- VYNE N/A
- Revenue Next Year
- KTCC N/A
- VYNE $20.00
- P/E Ratio
- KTCC N/A
- VYNE N/A
- Revenue Growth
- KTCC N/A
- VYNE 18.16
- 52 Week Low
- KTCC $2.50
- VYNE $1.57
- 52 Week High
- KTCC $6.14
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- KTCC 39.92
- VYNE 27.29
- Support Level
- KTCC $2.53
- VYNE $1.63
- Resistance Level
- KTCC $2.69
- VYNE $1.86
- Average True Range (ATR)
- KTCC 0.09
- VYNE 0.16
- MACD
- KTCC 0.02
- VYNE 0.00
- Stochastic Oscillator
- KTCC 48.15
- VYNE 0.00
About KTCC Key Tronic Corporation
Key Tronic Corp is an electronic manufacturing service provider. The company provides electronic manufacturing services to original equipment manufacturers in the United States and globally. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly, component selection, sourcing and procurement, logistics, and new product testing and production. The firm derives a majority of its revenue from the United States.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.